SPARC Q2 FY27 Results: Loss Narrows to Rs 2,458 Lakhs
NiveshIQ
NSE: SPARC · Healthcare
Sun Pharma Advanced Research Company Ltd.
₹175.09▼ ₹1.37 (-0.78%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on SPARC. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Sun Pharma Advanced Research Company Ltd.
Sun Pharma Advanced Research Company Limited (SPARC) specializes in R&D of novel pharmaceutical products, focusing on both therapeutic and diagnostic innovations. Its flagship pipeline includes Sezaby, a benzyl alcohol and propylene glycol‑free phenobarbital sodium injection for neonatal seizures, SPARC‑121 for alopecia areata, and SPARC‑122, an anti‑MUC1 antibody‑drug conjugate targeting multiple cancers. The company also develops PDP‑716 for open‑angle glaucoma, expanding its portfolio into ophthalmology. In FY27 Q2, SPARC narrowed its loss to ₹2,458 lakhs, reflecting improved cost management amid ongoing R&D investments. Revenue stood at ₹1,909 crore with a net income of ₹1,584 crore, underscoring a strong commercial base despite recent profitability swings. SPARC’s competitive edge lie
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹75.55 Cr -68.36% | ₹71.77 Cr -5.00% | ₹1,879 Cr +2518.32% |
| EBITDA Margin | -532.23% | -450.24% | 85.08% |
| Net Profit | ₹1,556 Cr | ||
| EPS | ₹-11.93 | ₹-10.55 | ₹47.86 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Sun (SPARC.NS) Stock Analysis: Range-Bound Near ₹182.98 2026-10-29 - Volume Profile
Sun Pharma Advanced Research Co. Ltd. Estimates – BSE:SPARC
🔒
+ 3 more stories about Sun Pharma Advanced Research Company Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q2FY27 results: revenue ₹30 Cr, PAT ₹-26 Cr, EPS ₹-0.75, EBITDA margin -151.9%. Growth context: revenue YoY +282.1%, revenue QoQ -24.8%, PAT QoQ +25.0%.
Recent corporate activity highlights product launches, approvals, and therapy-mix improvement and R&D investments and te...
FY26 (last completed FY): revenue ₹1, 879 Cr, PAT ₹1, 556 Cr, EBITDA margin 85.1%, EPS ₹47.86. Year-on-year: revenue YoY...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for SPARC
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track SPARC alongside your other holdings
Unlock full SPARC research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Sun Pharma Advanced Research Company Ltd.?
NiveshIQ detects active intelligence signals for Sun Pharma Advanced Research Company Ltd. (SPARC) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Sun Pharma Advanced Research Company Ltd.?
Sun Pharma Advanced Research Company Ltd. operates in the Healthcare sector with a market capitalisation of ₹562,071.4L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.